In June 2018, two currently open trials within the CRUK Combinations Alliance Portfolio have successfully defined their recommended phase 2 dose within the Dose Escalation Phase of the Trial, and have now opened their randomised expansion cohorts to patients in the target cancer type and setting via the ECMC network.
Research nurses are a vital part of the ECMC network and last month (April), the Programme Office held a training day for research nurses who are new to working in early phase cancer research. The aim of the day was to equip new early phase research nurses to deliver high quality, patient-centred care, within the regulatory framework. Twenty-five new research nurses were joined by eleven senior research nurses in Edinburgh to share their experiences and any apprehensions about such a demanding role.
To celebrate International Clinical Trials Day 2018 the Cancer Research UK Centre for Drug Development (CDD) are recognising staff who work across clinical trials by awarding them with a 'CDD Clinical Trial Heroes Award'. This years recipients include members from the ECMC network.
You can read the full list of winners and their reasons for winning below.
Due to the large number of applications received, the HRA are bringing forward the next round of recruitment for MPEs and CREs to register to become HRA Radiation Assurance Reviewers. The closing date for applications is Friday 6th April.
As part of the HRA's commitment to continuously improving the support they provide to the research community, they are introducing a process to improve the quality and consistency of research applications involving ionising radiation.
The Combinations Alliance partners with the ECMC Network to drive new combination therapies, including drug-radiotherapy combinations. ECMC studies such as PIONEER and PARADIGM-2 have been previously highlighted as successes in this area.
In January 2018 over 100 people from across the ECMC network came to Manchester to attend the sixth annual two day Junior Investigator Network Group (JING): Training the Next Generation event. This two day residential is aimed at junior investigators wishing to pursue and develop in the area of early phase trials and translational research within the ECMCs. Attendees included trainees, faculty, speakers and patient and public involvement representatives.
A collaborative workshop relating to definitions of complex trial designs was successfully held on 5 February 2018 in partnership with regulatory bodies (Health Research Authority, Medicines and Healthcare products Regulatory Agency (MHRA)) and other stakeholders including the research community (ECMC, Cancer Research UK, and Clinical Trials Units), devolved administrations and industry associations (The Association of the British Pharmaceutical Industry and UK BioIndustry Association).